Dong-A Socio, Alteogen & DMBio signs contract service agreement of macular degeneration treatment

Published: 2017-09-29 16:26:00
Updated: 2017-09-29 14:29:43

Alteogen(CEO Soon-Jae Park), a company which are developing a biosimilar of macular degeneration treatment ‘Eylea,’ announced on the 28th that it signed a Eylea biosimilar manufacturing agreement with DMBio(Byung-Jo Min, Kawasaki Yoshikuni) and Dong-A Socio Holdings(CEO Jong-Hyun Han).

Under the...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email:

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.